tbuckley/cabot-search huggingface dataset:
In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
Authors: Issa F. Khouri, Dawen Sui, Francesco Turturro, William D Erwin, Roland L Bassett, Martin Korbling, Rosamar Valverde, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Qaiser Bashir, Stefan O. Ciurea, Betul Oran, Amanda Olson, Uday R. Popat, Krina K Patel, Muzaffar H. Qazilbash, Michelle A. Fanale, Luis E. Fayad, Loretta Nastoupil, Jason R Westin, Alison M Gulbis, L. Jeffrey Medeiros, Ken H. Young, Aaron Jessop
Journal: Blood (2015)
The Olfactory Neural Epithelium As a Tool in Neuroscience
Authors: Joëlle Lavoie, Patricia Gassó Astorga, Hadar Segal-Gavish, YeeWen Candace Wu, Youjin Chung, Nicola G. Cascella, Akira Sawa, Koko Ishizuka
Journal: Trends in Molecular Medicine (2017)
P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes
Authors: Nguyen Johnny, Kathy L McGraw, Rami S. Komrokji, David Sallman, Najla H. Al Ali, Eric Padron, Jeffrey E Lancet, Lynn C. Moscinski, Alan F. List, Ling Zhang
Journal: Blood (2015)
The Prognostic Role of Jagged-1 Protein Expression In Acute Myeloid Leukemia Patients
Authors: Agnieszka Wierzbowska, Agnieszka Pluta, Konrad Stepka, Magdalena Czemerska, Barbara Cebula-Obrzut, Anna Krawczynska, Olga Grzybowska-Izydorczyk, Piotr Smolewski, Tadeusz Robak
Journal: Blood (2010)
The Innate Immune System Favors Emergency Monopoiesis at the Expense of DC Differentiation to Control Bacterial Infections
Authors: Kristin Bieber, Karina A. Pasquevich, Manina Günter, Matthias Grauer, Oliver Pötz, Ulrike Schleicher, Tilo Biedermann, Sandra Beer-Hammer, Hans-Jörg Bühring, Hans-Georg Rammensee, Lars Zender, Ingo B. Autenrieth, Lothar Kanz, Claudia Lengerke, Stella E. Autenrieth
Journal: Blood (2014)
Preliminary Experience of the Pakistani Network for the Cure and Prevention of Thalassaemia Supported by the Cure2Children Foundation.
Authors: Lawrence B. Faulkner, Tahir Shamsi, Saqib Ansari, Tasneem Farzana, Sadaf Khalid, Luigi Clemente, Naila Yaqub, Tahira Zafar, Rashid Kamran, Yasir Iqbal, Pietro Sodani, Cristiano Gallucci, Buket Erer, Guido Lucarelli
Journal: Blood (2009)
Socio-Demographic Parameters Including Race, As Predictors of Depression in Patients with Hematologic Malignancies
Authors: Amanda Shreders, Shehzad Niazi, David Hodge, Nicolette Chimato, Megha Kureti, Navya Kirla, Abhisek Swaika, Elaine Gustetic, Renee Foster, Kimberly Nelson, Asher Chanan-Khan, Sikander Ailawadhi
Journal: Blood (2015)
Gene Expression Profiling in AML and MDS Identifies Genes Located on 5q Which Are Consistently Lower Expressed in Cases with 5q Deletion as Compared to Cases with Normal Karyotype.
Authors: Claudia Schoch, Alexander Kohlmann, Wolfgang Kern, Sylvia Merk, Wolfgang Hiddemann, Martin Dugas, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2004)
Enhancement of Natural Killer Cell Interferon-Gamma Production By the Derivatives of the Natural Product Phyllanthusmins Via TLR-Mediated NF-Kb and STAT3 Signaling Pathways
Authors: Luxi Chen, Long Yi, Yuning Ren, Jianying Zhang, A. Douglas Kinghorn, Michael A. Caligiuri, Jianhua Yu
Journal: Blood (2015)
Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer.
Journal: Journal of Clinical Oncology (1985)

A prospective randomized trial to assess the impact of adding oophorectomy to adjuvant chemotherapy has been conducted in premenopausal patients with operable breast cancer and with metastases in four or more axillary lymph nodes. Following at least total mastectomy and axillary clearance, 327 evaluable patients were randomized to adjuvant oophorectomy followed by chemotherapy with cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F), and prednisone (p) or to CMFp alone. At 48 months of median follow-up, no statistically significant differences between regimens in terms of disease-free survival or overall survival were demonstrated, even for patients with steroid hormone receptor-containing tumors. A high incidence of amenorrhea (89%) due to ovarian function suppression was observed for the group receiving CMFp alone. Supplementation of the adjuvant therapy regimen by surgical oophorectomy is rendered superfluous by this effect of cytotoxic treatment. The addition of oophorectomy to combination chemotherapy with CMFp cannot be recommended as adjuvant treatment for high-risk (four or more axillary lymph nodes involved) premenopausal patients with operable breast cancer.
The Impact of Comorbidities on Clinical Outcome of Patients with Myelodysplastic Syndromes: A Real-Life Survey
Authors: Enrico Balleari, Chiara Salvetti, Andrea Bacigalupo, Gianluca Forni, Marco Gobbi, Riccardo Ghio, Marco Scudeletti, Rodolfo Tassara, Giovanni Berisso, Tullio Calzamiglia, Eleonora Arboscello, Germana Beltrami, Micaela Bergamaschi, Maurizio Cavalleri, Lisette Del Corso, Serena Favorini, Rosa Filiberti, Riccardo Goretti, Maurizio Miglino, Laura Mitschoning, Elisa Molinari, Omar Racchi, Marino Clavio
Journal: Blood (2014)
Cyclin D1 Deregulation in Mantle Cell Lymphoma: Tethering of the Cyclin D1 Promoter and 3′ Immunoglobin Enhancers by CTCF and Nucleophosmin.
Authors: Elliot M. Epner, Hui Liu, Wang Jin, Jing Huang, Craig R. Nichols, Richard T. Maziarz
Journal: Blood (2004)
Coca-Cola is sued over claims of misleading advertising
Authors: Bob Roehr
Journal: BMJ (2017)

Coca-Cola has been charged with “misleading and deceptive advertising practices around the consumption of sugar-sweetened beverages” in a lawsuit filed in a US federal court in Oakland, California.

The lawsuit, brought by the Praxis Project, a local social change organization, in collaboration with the national advocacy group the Center for Science in the Public Interest, accuses the company of violating California’s Unfair Competition Law and False Advertising Law.

The defendants, who include the American Beverage Association, “represented falsely that sugar-sweetened beverages are not scientifically linked to obesity, diabetes, and cardiovascular disease, and have waged an aggressive campaign of disinformation about …
Ancestim (SCF) and High-Dose Twice-Daily Filgrastim (G-CSF) Is Superior to G-CSF Alone or Cyclophosphamide Plus G-CSF for Mobilization of Peripheral Blood Stem Cells (PBSC) in Patients with Indolent Lymphoproliferative Disorders Previously Treated with Fludarabine; Results of a Historically-Controlled Phase-II Study.
Authors: John Francis Seymour, Sue Morgan, Miles Prince, David Alan Westerman, Max M. Wolf, Dennis A. Carney, Kally Yuen
Journal: Blood (2006)
Essential Role of Jun Family Transcription Factors in PU.1-Induced Leukemic Stem Cell Transformation.
Authors: Ulrich Steidl, Frank Rosenbauer, Roel G.W Verhaak, Xuesong Gu, Hasan H. Otu, Shakir Kolia, Bronwyn M. Owens, Steffen Klippel, Katharina Wagner, Manuel Aivado, Emmanuelle Passegue, Towia A. Libermann, Ruud Delwel, Daniel G. Tenen
Journal: Blood (2005)
Impact of Highly Conserved HLA Haplotype on Acute Graft-Versus-Host Disease in Unrelated Bone Marrow Transplantation
Authors: SatoKo Morishima, Seishi Ogawa, Takakazu Kawase, Aiko Matsubara, Yasuhito Nanya, Koichi Kashiwase, Hiroo Saji, Hidetoshi Inoko, Shunichi Kato, Yoshihisa Kodera, Takehiko Sasazuki, Yasuo Morishima
Journal: Blood (2008)
Reversive Loss of Pulmonary Function Induced by Acute Chest Syndrome: A Report from the National Acute Chest Syndrome Study Group (NACSG).
Authors: Lynne Neumayr, C. Morris, A. Wen, A. Earles, S. Robertson, M. Abboud, S. Ballas, I. Browning, R. Bellevue, C. Daeschner, P. Groncy, H.A. Hume, R. Iyer, L. McMahon, M. Moncino, E. Orringer, P. Swerdlow, P. Waldron15, R. Ware, E. Vichinsky
Journal: Blood (2005)
Aspirin for frequent episodic tension-type headache has limited evidence
Authors: Susan Mayor
Journal: BMJ (2017)

Evidence of aspirin’s efficacy for relieving acute pain in people with frequent episodic tension-type headache is limited, a Cochrane review of randomised studies has found.1

Frequent episodic tension-type headache is very common, its global prevalence of 21% making it the second most prevalent condition after dental caries. This type of headache is diagnosed in people with at least 10 episodes of tension-type headache in their lifetime who have two to 14 days with headache each month. Aspirin is one of several analgesics suggested for treatment.

Researchers searched medical databases for randomised, double blind …
Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia
Authors: Muhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, Elisabeth Paietta, Janis Racevskis, Christina Chen, Eytan M. Stein, Robert E Gallagher, Jacob M. Rowe, Frederick R. Appelbaum, Bayard L. Powell, Richard A. Larson, Neal S. Young, Martin S. Tallman
Journal: Blood (2014)
Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes
Authors: Jinghan Su, Huiping Sun, Qingshuo Meng, Pengcheng Zhang, Qi Yin, Yaping Li
Journal: Theranostics (2017)

Mesoporous silica nanoparticles (MSNs), with their large surface area and tunable pore sizes, have been widely applied for anticancer therapeutic cargos delivery with a high loading capacity. However, easy aggregation in saline buffers and limited blood circulation lifetime hinder their delivery efficiency and the anticancer efficacy. Here, new multifunctional MSNs-supported red-blood-cell (RBC)-mimetic theranostic nanoparticles with long blood circulation, deep-red light-activated tumor imaging and drug release were reported. High loading capacities were achieved by camouflaging MSNs with RBC membrane to co-load an anticancer drug doxorubicin (Dox) (39.1 wt%) and a near-infrared photosensitizer chlorin e6 (Ce6) (21.1 wt%). The RBC membrane-coating protected drugs from leakage, and greatly improved the colloidal stability of MSNs, with negligible particle size change over two weeks. Upon an external laser stimuli, the RBC membrane could be destroyed, resulting in 10 times enhancement of Dox release. In a 4T1 breast cancer mouse model, the RBC-mimetic MSNs could realize in vivo tumor imaging with elongated tumor accumulation lifetime for over 24 h, and laser-activated tumor-specific Dox accumulation. The RBC-mimetic MSNs could integrate the Ce6-based photodynamic therapy and Dox-based chemotherapy, completely suppress the primary tumor growth and inhibit metastasis of breast cancer, which could provide a new strategy for optimization of MSNs and efficient anticancer drug delivery.
PSMA Uptake in Mediastinal Sarcoidosis
Authors: Philip Junior Ardies, Pieterjan Gykiere, Lode Goethals, Johan De Mey, Frank De Geeter, Hendrik Everaert
Journal: Clinical Nuclear Medicine (2017)

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein which is frequently overexpressed on prostate cancer cells. Ga-PSMA PET/CT plays an increasing role in prostate cancer management. However, growing evidence suggests increased PSMA uptake in a variety of other malignant tumor entities and in some benign lesions. This report describes PSMA uptake in numerous thoracic lymph nodes in a patient with known mediastinal sarcoidosis. Knowledge and recognition of these possibilities are important to avoid scan misinterpretation.
Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML).
Authors: Guido Marcucci, W. Stock, G. Dai, S. Liu, R. Klisovic, M. I. Klisovic, D. Sher, L. Huynh, S. Frankel, W. Blum, R. A. Larson, M. R. Grever, J. C. Byrd, K. K. Chan
Journal: Blood (2004)
David Oliver: Older doctors revisited
Authors: David Oliver
Journal: BMJ (2017)

BerkshireI've never had a response to a column quite like that to Keeping Older Doctors in the Job. 1 As well as several public rapid responses, including an inspirational paean to rural general practice from Dr James Douglas, 2 I received over 100 private emails.I calculate the median respondent's age as 68.Others replied on to #olderdoctors.My respondents weren't a scientifically constructed sample, and they may show self selecting response bias.Surgeons, GPs, anaesthetists, and then psychiatrists accounted for eight in 10.I've picked out some key themes and anonymised the findings.
The pattern of HER-2/neu release in benign and malignant diseases
Authors: P. Stieber, H. J. Roth, J. Stemmler, H. Schmidt, M. Untch, B. Liedl, R. Hatz, D. Nagel, V. Heinemann
Journal: Journal of Clinical Oncology (2005)

618 Background: HER-2/neu (human epidermal growth factor receptor 2) overexpression in breast cancer tissue became within a short period of time an independent prognostic factor indicating the possibility of an antibody treatment with trastuzumab (Herceptin). The determination of HER-2/neu in blood could offer a less invasive and more reproducible method to initiate and control therapy of metastatic disease but requires a high degree of tumor as well as organ related specificity. Methods: As recommended by the EGTM (European Group on Tumor Markers), we investigated the HER-2/neu serum levels (ELISA, Bayer Diagnostics, US) in a broad variety of healthy individuals, benign and untreated malignant diseases, in total 1056 samples. Results: The median concentration of HER-2/neu in healthy individuals was 8.5 ng/ml (range 6–14.5). In benign diseases (n=431) the medians varied between 6 and 10 ng/mL, only in chronic liver diseases the 95% percentile was higher as compared to healthy individuals (range up to 32 ng/ml). The median HER-2/neu-values of all non metastatic cancer patients (colorectal, stomach, liver, pancreatic, breast; ovarian, bladder, kidney, lung; n=386) were comparable to healthy individuals (8–11 ng/ml) the 95%percentiles were increased up to 30 ng/ml in gastrointestinal tumors and breast cancer. Most metastatic tumors (n=303) showed no increased release of HER-2/neu, in metastatic breast cancer the median was 12 ng/ml, the 95%percentile was 215 ng/ml with values reaching up to 11000 ng/m, a specificity of 100% versus all other benign and malignant groups was reached at 40 ng/ml. Considering the immunohistochemical HER-2/neu-status of the primary breast tumor, 50% of the HER-2/neu 3+ tumors and 42% of the HER-2/neu 0–2+ tumors released HER-2/neu shed antigen > 40 ng/ml at the time of metastatic disease. Conclusions: A HER-2/neu concentration > 40 ng/ml in breast cancer patients allows the statement that this release is due to metastatic spread of breast cancer and that this release may also take place in metastases from patients without HER-2/neu overexpression in their primary tumors. Prospective observation and intervention trials are needed to lead these findings into clinical application and therapeutic decision making. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer
Anti-GvHD Effect of Antithymocyte Globulin Is Mediated by Antibodies Binding to T Cells and Regulatory NK Cells, and Less So or Not at All by Antibodies Binding to Other Mononuclear Cell Subsets
Authors: Mette Hoegh-Petersen, Minaa Amin, Yiping Liu, Alejandra Ugarte-Torres, Tyler S Williamson, Peter Podgorny, James A Russell, Jan Storek
Journal: Blood (2010)
Prognostic Impact of Fc Gamma-Receptor Polymorphisms and Efficacy of Rituximab in Children and Adolescents with Mature Aggressive B-NHL
Authors: Birgit Burkhardt, Deniz Yavuz, Martin Zimmerman, Jutta Schieferstein, Edita Kabickova, Andishe Attarbaschi, Jasmin Lisfeld, Bettina R. Bonn, Alfred Reiter, Christine Damm-Welk
Journal: Blood (2012)
Impact of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT).
Authors: Florent Mallard, Eolia Brissot, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Viviane Dubruille, Steven Legouill, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Beatrice Saulquin, Philippe Moreau, Jean-Luc Harousseau, Mohamad Mohty
Journal: Blood (2008)
The Characteristics of Hemorrhagic Cystitis After Allogeneic Stem Cell Transplantation, and Possible Predictive Value of Absolute Lymphocyte Count for Clinical Outcome.
Authors: Seung-Ah Yahng, Byung-Sik Cho, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park
Journal: Blood (2010)
Primary Acute Myeloid Leukemic Blasts Display Constitutive Serine 585 Phosphorylation within the 14-3-3 Binding Motif of the GM-CSF/IL-3 Receptor Required for Survival Signalling.
Authors: Daniel Thomas, Jason Powell, Szu-Hee Lee, Angel F. Lopez, Guthridge Mark
Journal: Blood (2005)
Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia
Authors: Gregory Corder, Vivianne L Tawfik, Dong Wang, Elizabeth I Sypek, Sarah A Low, Jasmine R Dickinson, Chaudy Sotoudeh, J David Clark, Ben A Barres, Christopher J Bohlen, Grégory Scherrer
Journal: Nature Medicine (2017)
Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.
Authors: Ronald P. Taylor, Andrew W. Pawluczkowycz, Margaret A. Lindorfer, Jan G. J. van de Winkel, Frank J. Beurskens, Paul W. H. I. Parren
Journal: Blood (2008)
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Authors: Annette T. Byrne, Denis G. Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S. Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A. Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino
Journal: Nature reviews. Cancer (2017)
The neuronal transcription factor NPAS4 is a strong inducer of sprouting angiogenesis and tip cell formation
Authors: Jennifer Susanne Esser, Anne Charlet, Mei Schmidt, Sophia Heck, Anita Allen, Achim Lother, Daniel Epting, Cam Patterson, Christoph Bode, Martin Moser
Journal: Cardiovascular Research (2016)

Regarding branching morphogenesis, neurogenesis and angiogenesis share common principle mechanisms and make use of the same molecules. Therefore, the investigation of neuronal molecules involved in vascular morphogenesis provides new possibilities for pro-angiogenic approaches in cardiovascular diseases.In this study, we investigated the role of the neuronal transcription factor NPAS4 in angiogenesis.Here, we demonstrate that the neuronal transcription factor NPAS4 is expressed in endothelial cells of different origin using reverse transcription PCR and western blot analysis. To investigate how NPAS4 affects endothelial cell function, NPAS4 was overexpressed by plasmid transfection or depleted from human umbilical vein endothelial cells (HUVECs) by specific siRNAs. In vitro HUVEC sprouting assays showed that sprouting and branching of endothelial cells was enhanced by NPAS4 overexpression. Consistently, silencing of NPAS4 resulted in reduced HUVEC sprouting and branching. Mechanistically, we identified as target gene vascular endothelial adhesion molecule VE-cadherin to be involved in the pro-angiogenic function of NPAS4. In endothelial cell mosaic spheroid sprouting assays, NPAS4 was involved in tip cell formation. In vivo experiments in mouse and zebrafish confirmed our in vitro findings. NPAS4-deficient mice displayed reduced ingrowth of endothelial cells in the Matrigel plug assay. Consistent with a regulatory role of NPAS4 in endothelial cell function silencing of NPAS4 in zebrafish by specific morpholinos resulted in perturbed intersegmental vessels growth.NPAS4 is expressed in endothelial cells, regulates VE-cadherin expression and regulates sprouting angiogenesis.
Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts
Authors: Yutaka Hattori, Maiko Matsushita, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa
Journal: Blood (2014)
Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia
Authors: John C. Riches, Ajanthah Sangaralingam, Shahryar Kiaii, Tracy Chaplin, Demet Cekdemir, Sameena Iqbal, Alan G. Ramsay, John G. Gribben
Journal: Blood (2011)
Effector Regulatory T Cell Differentiation and Immune Homeostasis Depend on the Transcription Factor Myb
Authors: Sheila Dias, Angela D’Amico, Erika Cretney, Yang Liao, Julie Tellier, Christine Bruggeman, Francisca F. Almeida, Jamie Leahy, Gabrielle T. Belz, Gordon K. Smyth, Wei Shi, Stephen L. Nutt
Journal: Immunity (2017)
Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.
Authors: Nieves Diaz, Eugeny A. Osmanov, Yulia A. Alexeeva, Mikhail Yu Byakhov, Oleg N. Lipatov, Sergey K. Kravchenko, Ilya S. Zuzgin, Felix T. Garzon, Laurence Elias, Philippe Solal-Celigny
Journal: Blood (2005)
GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration
Authors: Jiusheng Deng, Yanqiu Li, Andrea Pennati, Shala Yuan, Jian Hui Wu, Edmund K. Waller, Jacques Galipeau
Journal: Molecular Therapy (2017)

Hematopoietic stem cells (HSCs) have the capacity to self-renew and differentiate into hematopoietic cells and have been utilized to replace diseased bone marrow for patients with cancers and blood disorders. Although remarkable progress has been made in developing new tools to manipulate HSCs for clinic use, there is still no effective method to expand HSCs in vivo for quick repopulation of hematopoietic cells following sublethal irradiation. We have recently described a novel synthetic cytokine that is derived from the fusion of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4; named as GIFT4), and we have now discovered that GIFT4 fusokine promotes long-term hematopoietic regeneration in a B cell-dependent manner. We found that GIFT4 treatment triggered a robust expansion of endogenous bone marrow HSCs and multipotent progenitors in vivo. Delivery of GIFT4 protein together with B cells rescued lethally irradiated mice. Moreover, adoptive transfer of autologous or allogeneic GIFT4-treated B cells (GIFT4-B cells) enhanced long-term hematopoietic recovery in radiated mice and prevented the mice from irradiation-induced death. Our data suggest that GIFT4 as well as GIFT4-B cells could serve as means to augment HSC engraftment in the setting of bone marrow transplantation for patients with hematological malignancy.
Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.
Authors: Mark S. Kaminski, Melissa Tuck, Judith Estes, Arne Kolstad, Charles Warren Ross, Denise Regan, Thierry Horner, Vanessa C. Williams, Tina Vleisides, Richard L. Wahl
Journal: Blood (2009)